Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02086890
Other study ID # 01311402F
Secondary ID R21EY023720
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 2014
Est. completion date December 2024

Study information

Verified date June 2023
Source Nova Southeastern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Measures of vision in RP patients receiving promising therapy using transcorneal electrical stimulation.


Description:

Retinitis pigmentosa (RP) is a slowly progressive retinal degeneration for which there is no proven treatment. Patients are interested in trying alternative therapies to try to reduce their vision loss, but only limited research evidence exists to support their use and potential benefit. The goal of this research project is to gain a better understanding of possible changes in ocular and retinal blood flow and measures of vision in RP patients receiving two promising therapies, electroacupuncture and transcorneal electrical stimulation. We are currently only doing transcorneal electrical stimulation.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 21
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18+ - Diagnosis of retinitis pigmentosa (RP) - Best-corrected visual acuity better than 20/400 in at least one eye - More than 20% loss of Goldmann Visual Field area (III4e test target) in at least one eye - Able and willing to participate in all study visits for a ~4-6 month period - Provide informed consent Exclusion Criteria: - Very severe vision losses in both eyes (e.g., hand motions or light perception only) with difficulty performing the proposed vision tests - Vision loss due to ocular diseases other than RP, cystoid macular edema, or cataracts - Schedules do not permit participation in all study visits - Previous acupuncture or TES treatment for RP - Inability to understand study procedures or communicate responses to visual stimuli in a consistent manner (cognitive impairment) - Dementia; Long or short-term memory loss - Unable to read or speak English - Smoking, excessive alcohol, or illegal drug use - Receiving current psychiatric care (i.e. unstable emotional and mental health status) - History of excessive bleeding - Reduced general health and/or systemic medications that may diminish the potential response to the electroacupuncture treatments - Implanted cardiac pacemaker - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Electro-acupuncture

Laser Acupuncture

Transcorneal Electrical Stimulation

Sham Electro-acupuncture

Sham laser acupuncture

Sham transcorneal electrical stimulation


Locations

Country Name City State
United States Nova Southeastern University; College of Optometry Fort Lauderdale Florida

Sponsors (2)

Lead Sponsor Collaborator
Nova Southeastern University National Eye Institute (NEI)

Country where clinical trial is conducted

United States, 

References & Publications (4)

Bittner AK, Gould JM, Rosenfarb A, Rozanski C, Dagnelie G. A pilot study of an acupuncture protocol to improve visual function in retinitis pigmentosa patients. Clin Exp Optom. 2014 May;97(3):240-7. doi: 10.1111/cxo.12117. Epub 2013 Oct 29. — View Citation

Bittner AK, Seger K, Salveson R, Kayser S, Morrison N, Vargas P, Mendelsohn D, Han J, Bi H, Dagnelie G, Benavente A, Ramella-Roman J. Randomized controlled trial of electro-stimulation therapies to modulate retinal blood flow and visual function in retini — View Citation

Bittner AK, Seger K. Longevity of visual improvements following transcorneal electrical stimulation and efficacy of retreatment in three individuals with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2018 Feb;256(2):299-306. doi: 10.1007/s00417- — View Citation

Kayser S, Vargas P, Mendelsohn D, Han J, Bi H, Benavente A, Bittner AK. Reduced Central Retinal Artery Blood Flow Is Related to Impaired Central Visual Function in Retinitis Pigmentosa Patients. Curr Eye Res. 2017 Nov;42(11):1503-1510. doi: 10.1080/027136 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Significant changes from baseline in Goldmann visual field area in both eyes Using Haig-Streit Octopus perimeter twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation
Secondary Significant changes from baseline in best-corrected ETDRS visual acuity at both 2 weeks and 6 weeks post-intervention initiation Using Pelli-Robson visual acuity charts twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation
Secondary Changes in Macular edema Optical Coherence Tomography (OCT) Using Optical Coherence Tomography twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation
Secondary Significant changes from baseline in contrast sensitivity at both 2 weeks and 6 weeks post-intervention initiation Using Adaptive Sensory Technology Quick CSF twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation
Secondary Significant changes from baseline in Dark adaptation function at both 2 weeks and 6 weeks post-intervention initiation Using the AdaptDx by Maculogix twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Completed NCT04983914 - Retrospective NIS to Evaluate the Patient Benefit of TES
Recruiting NCT03845218 - Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
Completed NCT00231010 - Molecular Genetics of Retinal Degenerations
Active, not recruiting NCT04611503 - PDE6A Gene Therapy for Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Recruiting NCT01914913 - Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT01949623 - Biomarkers In Retinitis Pigmentosa (BIRP) N/A
Completed NCT01835002 - Transcorneal Electrical Stimulation - Multicenter Safety Study N/A
Completed NCT00407602 - Argus® II Retinal Stimulation System Feasibility Protocol N/A
Completed NCT00515814 - Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors N/A
Completed NCT00100230 - DHA and X-Linked Retinitis Pigmentosa Phase 2
Active, not recruiting NCT00378742 - Repository for Inherited Eye Diseases
Terminated NCT05085964 - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa Phase 2
Recruiting NCT05805007 - Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa Early Phase 1
Recruiting NCT05909488 - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II Phase 2/Phase 3
Recruiting NCT06291935 - Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene Phase 1
Recruiting NCT03078309 - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients Early Phase 1
Completed NCT04238858 - Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa N/A
Active, not recruiting NCT01680510 - The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil Phase 1/Phase 2